Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.34 -4.34%

-$0.11 today

Market cap
$441.63M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 1.77M

Average 3.07M

Income Statement

Follow revenue through to earnings.

Revenue

$7.25M

FY 2025 · Annual

+1181.3% YoY

Operating Income

-$42.44M

FY 2025 · Annual

Net Income

-$17.41M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue208.38M1.5M392K566K7.25M
Cost of Revenue0000300K
Gross Profit208.38M1.5M392K566K6.95M
Gross Margin100.0%100.0%100.0%100.0%95.9%
Research & Development46.94M24.62M28.59M36.77M25.58M
Selling, General & Admin37.23M32.43M29.59M25.68M24.11M
Operating Expenses84.17M57.05M59.67M62.45M49.39M
Depreciation & Amortization237.08K1.38M568K613K300K
EBITDA124.45M(54.17M)(57.01M)(57.77M)(17.11M)
EBITDA Margin59.7%-3604.5%-14544.1%-10207.1%-236.0%
Operating Income124.21M(55.55M)(59.28M)(61.89M)(42.44M)
Operating Margin59.6%-3696.4%-15122.7%-10933.7%-585.2%
Interest Income004.9M3.9M0
Interest Expense00000
Other Income / Expenses(45.69K)1.38M6.94M35.45M25.03M
Income Before Tax124.16M(54.17M)(52.34M)(26.43M)(17.41M)
Pre-Tax Margin59.6%-3604.7%-13351.8%-4670.1%-240.1%
Income Tax Expense1.33M0000
Net Income122.83M(54.17M)(52.34M)(26.43M)(17.41M)
Net Margin58.9%-3604.7%-13351.8%-4670.1%-240.1%
EPS (Basic)1.78(0.77)(0.74)(0.37)(0.24)
EPS (Diluted)1.76(0.77)(0.74)(0.37)(0.24)
Weighted Avg Shares67.48M70.43M70.58M70.91M73.74M
Weighted Avg Shares (Diluted)68.07M70.43M70.58M70.91M73.74M

OVID Earnings Waterfall · TTM

NASDAQ:OVID · Revenue to Net Income

Key Ratios

EPS$-0.35
Gross Margin75.0%
Net Margin-1984.9%
P/E Ratio-0.5
P/S Ratio222.4

Analysis

$7.1M of revenue converted into -$24.2M of net income for the selected period. Gross margin is 75.0% and net margin is -1984.9%, showing how much revenue survives after costs and taxes. EPS is $-0.35, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
S-3S-3 filingNov 10, 2026
10-QQuarterly reportNov 10, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

How much revenue does OVID generate?

Ovid Therapeutics Inc. (OVID) reported $7.25M of revenue in fiscal 2025.

Is OVID profitable?

Ovid Therapeutics Inc. (OVID) reported -$17.41M of net income, with a net margin of -240.1%.